# A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

> **NCT01731600** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 68 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A

## Interventions

- **DRUG:** turoctocog alfa pegol

## Key facts

- **NCT ID:** NCT01731600
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-20
- **Primary completion:** 2014-09-15
- **Final completion:** 2018-09-28
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01731600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01731600, "A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT01731600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*